Depression and cerebrovascular disease: Could vortioxetine represent a valid treatment option?

Clinical Practice and Epidemiology in Mental Health

Volumn 11, Issue 1, 2015, Pages 144-149

  Carta, Mauro Giovanni ^a   Pala, Andrea Norcini ^b   Finco, Gabriele ^c   Musu, Mario ^c   Moro, Maria Francesca ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c Department of Medical Science University of Caglairi   (Italy)

Author keywords

Cerebrovascular disease; Major depressive disorders; Vascular depression; Vortioxetine

Indexed keywords

PLACEBO; VORTIOXETINE;

ARTERIAL PRESSURE; ARTICLE; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; DEPRESSION; DIGIT SYMBOL SUBSTITUTION TEST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; HUMAN; MAJOR DEPRESSION; NAUSEA; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN;

EID: 84928661838     PISSN: None     EISSN: 17450179     Source Type: Journal    
DOI: 10.2174/1745017901511010144     Document Type: Article

References (77)

1. Celermajer DS, Chow CK, Marijon E, Anstey NM, Woo KS. Cardiovascular disease in the developing world prevalences, patterns, and the potential of early disease detection. J Am Coll Cardiol 2012; 60(14): 1207-16.
2. Brott TG, Halperin JL, Abbara S, et al. ASA/ACCF/AHA/AANN/ AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/ SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. Circulation 2011; 124(4): E54-130. [Epub 2011/02/02].
3. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 2010; 121(7): 948-54.
4. Rocque BG, Jackson D, Varghese T, et al. Impaired cognitive function in patients with atherosclerotic carotid stenosis and correlation with ultrasound strain measurements. J Neurol Sci 2012; 322(1-2): 20-4. doi: 10.1016/j.jns.2012.05.020. [Epub 2012 Jun 1].
5. de Weerd M, Greving JP, Hedblad B, et al. Prediction of asymptomatic carotid artery stenosis in the general population: Identification of high-risk groups. Stroke 2014; 45(8): 2366-71.
6. Vieweg WV, Julius DA, Fernandez A, et al. Treatment of depression in patients with coronary heart disease. Am J Med 2006; 119(7): 567-73.
7. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases [no virgola] and decrements in health: Results from the World Health Surveys. Lancet 2007; 370: 851-8.
8. Egede LE. Major depression in individuals with chronic medical disorders: Prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry 2007; 29: 409-16.
9. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: A systematic review and meta-analysis. Diabet Med 2006; 23: 1165-73.
10. Hadidi N, Treat-Jacobson DJ, Lindquist R. Poststroke depression and functional outcome: A critical review of literature. Hear Lung 2009; 38: 151-62.
11. Carta MG, Lecca ME, Saba L, et al. Patients with Carotid Atherosclerosis who underwent or did not undergo carotid endarterectomy (CEA): Outcome on mood, cognition and quality of life. BMC Psychiatry Submitted.
12. Whooley MA, De JP, Vittinghoff E, et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008; 300: 2379-88.
13. Alexopoulos GS, Kiosses DN, Klimstra S, et al. Clinical presentation of the "depression-executive dysfunction syndrome" of late life. Am J Geriatr Psychiatry 2002; 10: 98-106.
14. Sneed JR, Culang-Reinlieb ME. The vascular depression hypothesis: An update. Am J Geriatr Psychiatry 2011; 19(2): 99-103.
15. Alexopoulos GS, Kiosses DN, Choi SJ, et al. Frontal white matter microstructure and treatment response of late-life depression: A preliminary study. Am J Psychiatry 2002; 159: 1929-32.
16. Krishnan KR, Taylor WD, McQuoid DR, et al. Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. Biological Psychiatry 2004; 55:390-7.
17. Krishnan V, Nestler EJ. Linking molecules to mood: New insight into the biology of depression. Am J Psychiatry 2010; 167: 1305-20.
18. Sneed JR, Culang ME, Keilp JG, et al. Antidepressant medication and executive dysfunction: A deleterious interaction in late-life depression. Am J Geriatr Psychiatry 2010; 18: 128-35.
19. Kim BS, Lee DH, Lee DW, et al. The role of vascular risk factors in the development of DED syndrome among an elderly community sample. Am J Geriatr Psychiatry 2011; 19(2): 104-14. doi: 10.1097/JGP.0b013e31820119b6.
20. Arauz A, Rodríguez-Agudelo Y, Sosa AL, et al. Vascular cognitive disorders and depression after first-ever stroke: The fogarty-Mexico stroke cohort. Cerebrovasc Dis 2014; 38(4): 284-9. [Epub ahead of print]
21. Taylor WD, MacFall JR, Payne ME, et al. Orbitofrontal cortex volume in late life depression: Influence of hyperintense lesions and genetic polymorphisms. Psychol Med 2007; 37: 1763-73.
22. Artero S, Tiemeier H, Prins ND, et al. Neuroanatomical localization and clinical correlates of white matter lesions in the elderly. J Neurol Neurosurg 2004; 75: 1304-8.
23. Rajkowska G, Miguel-Hidalgo JJ, Dubey P, et al. Prominent reduction in pyramidal neurons density in the orbitofrontal cortex of elderly depressed patients. Biological Psychiatry 2005; 58: 297-306.
24. Khundakar A, Morris C, Oakley A, Thomas AJ. Morphometric analysis of neuronal and glial cell pathology in the caudate nucleus in late-life depression. Am J Geriatr Psychiatry 2011; 19(2): 132-41.
25. Nabavi SF, Dean OM, Turner A, Sureda A, Daglia M, Nabavi SM. Oxidative stress and post-stroke depression: Possible therapeutic role of polyphenols? Curr Med Chem 2015; 22(3): 343-51.
26. Li F, Fei D, Sun L, et al. Neuroprotective effect of bone marrow stromal cell combination with atorvastatin in rat model of spinal cord injury. Int J Clin Exp Med 2014; 7(12): 4967-74.
27. Henry G, Williamson D, Tampi RR. Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence. Am J Alzheimers Dis Other Demen 2011; 26(3): 169-83. doi: 10.1177/ 1533317511402051.
28. Mazza M, Lotrionte M, Biondi-Zoccai G, Abbate A, Sheiban I, Romagnoli E. Selective serotonin reuptake inhibitors provide significant lower re-hospitalization rates in patients recovering from acute coronary syndromes: Evidence from a meta-analysis. J Psychopharmacol 2010; 24: 1785-92.
29. Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol 2011; 107: 972-9.
30. Liu X, Zhang J, Sun D, Fan Y, Zhou H, Fu B. Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia. Clin Interv Aging 2014; 9: 411-8. doi: 10.2147/CIA.S58830.
31. Kurumatani T, Takeda M. Vascular depression. Nihon Rinsho 2001; 59(8): 1574-7.
32. de Abajo FJ, Montero D, Rodriguez LA, Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 2006; 98: 304-10.
33. Kimura A, Iwamoto T. Acute massive gastrointestinal bleeding in the elderly. Nihon Ronen Igakkai Zasshi 2009; 46(3): 250-8.
34. FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide) 2011. Available at: Http://www.fda.gov/Drugs/DrugSafety/ucm 269086.htm.
35. Rieckmann N, Kronish IM, Shapiro PA, Whang W, Davidson KW. Serotonin reuptake inhibitor use, depression, and long-term outcomes after an acute coronary syndrome: A prospective cohort study. JAMA Intern Med 2013; 173(12): 1150-1. doi: 10.1001/ jamainternmed. 2013.910.
36. Oudman E. Is electroconvulsive therapy (ECT) effective and safe for treatment of depression in dementia? A short review. J ECT 2012; 28(1): 34-8.
37. Alexopoulos GS, Raue P, Arean P. Problem-solving therapy versus supportive therapy in geriatric major depression with executive dysfunction. Am J Geriatr Psychiat 2003; 11: 46-52.
38. Kiosses DN, Arean PA, Teri L, Alexopoulos GS. Home-delivered problem adaptation therapy (PATH) for depressed, cognitively impaired, disabled elders: A preliminary study. Am J Geriatr Psychiatry 2010; 18(11): 988-98. doi: 10.1097/JGP.0b013e3181d6947d
39. Koenig AM, Butters MA. Cognition in late life depression: Treatment considerations. Curr Treat Options Psychiatry 2014; 1(1): 1-14.
40. Westrich L, Pehrson A, Zhong H, et al. In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatr Clin Pract 2012; 16(Suppl 1): 47.
41. Mørk A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: A novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 2012; 340(3): 666-75.
42. Pehrson AL, Cremers T, Bétry C, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters - a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol 2013; 23(2): 133-45.
43. Artigas F. Serotonin receptors involved in antidepressant effects. Pharmacol Ther 2013; 137(1):119-31.
44. Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5- HT1A antagonists. Trends Neurosci 1996; 19(9): 378-83.
45. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014; 19(2): 121-33. doi: 10.1017/ S1092852913000540. [Epub 2013 Aug 1].
46. Dale E, Zhang H, Leiser SC, et al. Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippo campus. J Psychopharmacol 2014; 28(10): 891-902. doi: 10.1177/ 0269881114543719.
47. Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2014; 10: 1297-307. doi: 10.2147/ NDT.S41387.
48. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jørgensen M, Püschl A, Dalgaard L. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos 2012; 40(7): 1357-65.
49. Hussaini SM, Choi CI, Cho CH, Kim HJ, Jun H, Jang MH. Wnt signaling in neuropsychiatric disorders: Ties with adult hippocampal neurogenesis and behavior. Neurosci Biobehav Rev 2014; 47: 369-83. doi: 10.1016/j.neubiorev.2014.09.005. [Epub 2014 Sep 28].
50. Carta MG, Moro MF, Lorefice L, et al. The risk of Bipolar Disorders in Multiple Sclerosis. J Affect Disord 2014; 155: 255-60. doi: 10.1016/j.jad.2013.11.008.
51. Carta MG, Bhat KM, Preti A. GABAergic neuroactive steroids: A new frontier in bipolar disorders? Behav Brain Funct 2012; 8(1): 61.
52. Carta MG, Sorbello O, Moro MF, et al. Bipolar disorders and Wilson's disease. BMC Psychiatry 2012; 12(1): 52.
53. Hardoy MC, Serra M, Carta MG, Contu P, Pisu MG, Biggio G. Increased neuroactive steroid concentrations in women with bipolar disorder or major depressive disorder. J Clin Psychopharmacol 2006; 26(4): 379-84.
54. Bramham CR, Worley PF, Moore MJ, Guzowski JF. The immediate early gene arc/arg3.1: Regulation, mechanisms, and function. J Neurosci 2008; 28: 11760-7.
55. Guzowski JF, Lyford GL, Stevenson GD, et al. Inhibition of activity- dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. J Neurosci 2000; 20: 3993-4001.
56. Cates LN, Roberts AJ, Huitron-Resendiz S, Hedlund PB. Effects of lurasidone in behavior models of depression. Role of the 5-HT receptor subtype. Neuropharmacology 2013; 70C: 211-7.
57. Wesolowska A, Tatarczynska E, Nikiforuk A, Chojnacka-Wojcik E. Enhancement of the anti-immobility action of antidepressants by a selective 5-HT7 receptor antagonist in the forced swimming test in mice. Eur J Pharmacol 2007; 555: 43-7.
58. Roberts AJ, Hedlund PB. The 5-HT(7) receptor in learning and memory. Hippocampus 2012; 22: 762-71.
59. Guilloux JP, Mendez-David I, Pehrson A, et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology 2013; 73: 147-59. doi: 10.1016/ j.neuropharm.2013.05.014. [Epub 2013 May 28].
60. Pae CU, Wang SM, Han C, et al. Vortioxetine: A meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci. 2014; 39(6): 140120. doi: 10.1503/jpn.140120. [Epub ahead of print]
61. Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 2013; 16(2): 313-21.
62. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012; 22(7): 482-91.
63. Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y, Trivedi MH. A duloxetine-referenced, fixed dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult MDD patients; Poster presented at: American Psychiatry Association Annual Meeting; San Francisco, CA, May 18-22, 2013a.
64. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double- blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 2013b; 29(3): 217-26.
65. Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y, Trivedi MH. A randomized, double blind, parallel, placebo-controlled, fixed-dose study comparing the efficacy and safety of 2 doses of vortioxetine (LU AA21004) in acute treatment of adults with major depressive disorder; Poster presented at: American Psychiatry Association Annual Meeting; San Francisco, CA, May 18-22, 2013c.
66. Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with Major Depressive Disorder; Poster presented at: American Psychiatry Association Annual Meeting; San Francisco, CA, May 18-22, 2013a.
67. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. A doubleblind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2012; 15(5): 589-600.
68. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012; 73(7): 953-9.
69. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo- controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012; 27(4): 215-23.
70. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: A randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014; 29(3): 138-49.
71. McIntyre RS, Lophaven S, Olsen CK. Randomized, double-blind, placebo-controlled study of the efficacy of vortioxetine on cognitive function in adult patients with major depressive disorder (MDD); Poster presented at: 52nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP); Hollywood, FL, December 8-12, 2013.
72. Häggström L, Nielsen RZ, Poulsen L, Danchenko N. A randomised, double blind, active controlled study of vortioxetine (10-20 mg/day) versus agomelatine 25-50 mg/day) in adults with Major Depressive Disorder with inadequate response to antidepressant treatment; Poster presented at: 26th Congress of the European College of Neuropsychopharmacology (ECNP); Barcelona, Spain, October 5-9, 2013.
73. NCT01255787. Efficacy and safety study of vortioxetine (Lu AA21004) for treatment of major depressive disorder. Available: Http://clinicaltrials.gov/show/NCT01255787 [accessed 2014 Apr. 1].
74. Dragheim M, Nielsen RZ. A randomized, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) switched after inadequate response to SSRI or SNRI treatment (NCT01488071) [poster]. NCDEU 53rd Annual Meeting; Hollywood, FL, 2013 May 28-31.
75. Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012; 26(11): 1408-16.
76. du Jardin KG, Jensen JB, Sanchez C, Pehrson AL. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5- HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol 2014; 24(1): 160-71.
77. Theunissen EL, Street D, Hojer AM, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther 2013; 93(6): 493-501.